South Korea Healthcare Market Report 2026: HIRA, NHIS Reimbursement, and Biopharmaceutical Industry Intelligence

The South Korean healthcare market is estimated at USD 110–125 billion in 2026, representing approximately 9.7% of GDP. South Korea operates the NHIS (National Health Insurance Service), a single-payer universal insurance scheme covering the entire population, with copayments varying by care type. HIRA (Health Insurance Review and Assessment Service) reviews insurance claims and evaluates health technologies for coverage. South Korea has one of the world's highest medical utilisation rates — Koreans average approximately 16 outpatient visits per year — creating exceptional prescription drug and diagnostic device demand per capita.

The South Korean pharmaceutical market is estimated at USD 22–26 billion in 2026. MFDS (Ministry of Food and Drug Safety) regulates pharmaceutical registration and approval. HIRA conducts clinical benefit assessments for new drugs seeking NHIS coverage, while NHIS negotiates reimbursement prices. Korea has developed a significant domestic biopharmaceutical industry — Samsung Biologics (CDMO), Celltrion (biosimilars), and Daewoong Pharmaceutical (botulinum toxins, biosimilars) are global players. Korea was among the first countries to launch Celltrion's biosimilar infliximab (Remsima) globally, and Korean biosimilar companies supply GCC markets.

Korea's pharmaceutical market access process: (1) MFDS approval — Korea increasingly accepts EMA/FDA approval data under mutual recognition principles, reducing duplicative clinical requirements; (2) HIRA clinical assessment — HIRA evaluates whether the new drug demonstrates clinical benefit versus comparator; (3) NHIS reimbursement negotiation — NHIS negotiates price with manufacturer if HIRA clinical assessment is positive. Korea uses cost-effectiveness analysis (ICER) as part of the HIRA value assessment — medicines not meeting the threshold may receive conditional or restricted coverage. Risk-sharing agreements (RSAs) are common for high-cost products. Korea also has an Early Entry Assessment (EEA) pathway enabling patients to access promising treatments before full NHIS coverage.

The five largest therapy areas in the Korean pharmaceutical market by NHIS expenditure are: oncology (Korea has among the world's highest cancer incidence rates per capita — gastric cancer, colorectal cancer, thyroid cancer; major NHIS investment in immuno-oncology); immunology and biologics (biosimilar leadership — Celltrion, Samsung Bioepis dominate biosimilar supply domestically and export globally); cardiovascular (high-volume generic sector; branded differentiation in heart failure and anticoagulation); diabetes (GLP-1 agonists growing; high insulin volume); and CNS/psychiatry (high antidepressant and antipsychotic prescribing rates). Korea is a significant clinical trial hub — Samsung Medical Centre, Asan Medical Centre, and Seoul National University Hospital are among Asia's most active clinical trial sites.

South Korea is one of the world's largest and fastest-growing biopharmaceutical contract manufacturing hubs. Samsung Biologics (Incheon) operates the world's largest single-site biomanufacturing facility with 360,000L+ bioreactor capacity. Celltrion (Incheon) manufactures biosimilars distributed across 100+ countries. SK Bioscience and GC Pharma are major vaccine manufacturers. Korea's government K-BIO initiative and Bio Cluster at Incheon Free Economic Zone support biomanufacturing expansion. Korean CDMO capacity makes Korea a critical supplier of biosimilar and innovative biologic products globally — including for GCC markets where Korean biosimilars have significant market share.

MFDS (Ministry of Food and Drug Safety) is Korea's primary drug regulator, responsible for reviewing quality, safety, and efficacy data before a medicine may be marketed. The process typically opens with an optional pre-submission consultation, which is effectively mandatory for new biological products given their complexity, followed by a New Drug Application submitted in the Korean Common Technical Document (K-CTD) format that closely mirrors the ICH CTD structure used in the US, EU, and Japan. MFDS's technical review then runs approximately 12 months for standard applications, with a 6-month priority track available for products addressing serious or life-threatening conditions with no adequate alternative therapy. Because Korea is an ICH member, MFDS increasingly leans on clinical data already reviewed by trusted reference agencies such as the FDA and EMA, which can reduce duplicative local testing, although bridging studies with Korean patients are sometimes still requested where ethnic sensitivity in dosing or metabolism is a plausible concern.

The National Health Insurance Service (NHIS) is Korea's sole statutory health insurer, covering virtually the entire population under one national scheme rather than the multiple competing insurers found in Germany or the Netherlands. Funding comes primarily from payroll-based contributions shared between employees and employers, supplemented by government subsidies and a separate self-employed contribution track based on income and property, while a tax-funded Medical Aid programme covers low-income households who are exempt from NHIS premiums entirely. Because every provider bills the same national insurer, NHIS combined with HIRA's claims review creates a single, centrally administered reimbursement pathway with none of the plan-to-plan formulary variation seen in multi-payer systems. Patients typically face around 20% coinsurance for inpatient care and higher shares for outpatient visits depending on facility type, though an annual out-of-pocket ceiling protects households from catastrophic costs, with further copayment reductions available for designated rare and serious illnesses.

Risk-Sharing Agreements (RSAs) are confidential arrangements between HIRA/NHIS and a manufacturer that allow a high-cost medicine — most often an oncology or rare-disease therapy — to be listed on the NHI formulary despite failing to clear the standard cost-effectiveness threshold on list price alone. Common RSA structures used in Korea include price-volume agreements, where the effective price falls once cumulative sales exceed an agreed volume; expenditure caps that shift budget risk from NHIS back to the manufacturer; and outcome-based or coverage-with-evidence-development (CED) schemes, under which continued reimbursement depends on real-world data confirming the clinical benefit observed in trials. RSAs exist specifically to balance patient access to innovative cancer therapies against the sustainability pressure a single national payer faces from a growing pipeline of expensive biologic and cell-and-gene launches. For manufacturers, securing an RSA typically extends the overall NHIS listing timeline by several months beyond a standard HIRA clinical assessment, but it is frequently the only viable route to formulary access for premium-priced oncology products in Korea.

BioNixus delivers pharmaceutical and healthcare market research in South Korea: regulator-aware access intelligence, hospital consumption analogues, physician and payer qualitative programmes, and launch evidence under EphMRA and BHBIA governance with GDPR-aligned fieldwork for multinational sponsors. Teams receive decision-ready outputs validated against national policy and institution-level adoption—not desk extrapolation from unrelated regions.

BioNixus supports South Korea-based pharmaceutical companies expanding into GCC and MENA markets with SFDA and MOHAP regulatory intelligence, NUPCO and hospital procurement tracking in Saudi Arabia, UAE insurer and formulary research, physician panels across GCC countries, and comparative South Korea versus GCC market intelligence. GCC expansion is a distinct service line with its own tender and access calendars—see our GCC pharmaceutical market report for regional context. Launch assumptions should be validated market by market rather than from a single Gulf average.